The University of Chicago Header Logo

Connection

Mark J. Ratain to Camptothecin

Back to Details
This is a "connection" page, showing publications Mark J. Ratain has written about Camptothecin.
Mark J. Ratain
Connection Strength
6.139
Camptothecin
  1. Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol. 2014 Aug 01; 32(22):2328-34.
    View in: PubMed
    Score: 0.438
  2. Individualizing dosing of irinotecan. Clin Cancer Res. 2010 Jan 15; 16(2):371-2.
    View in: PubMed
    Score: 0.322
  3. Pharmacogenetic pathway analysis of irinotecan. Clin Pharmacol Ther. 2008 Sep; 84(3):393-402.
    View in: PubMed
    Score: 0.285
  4. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics. 2006 Dec; 7(8):1211-21.
    View in: PubMed
    Score: 0.260
  5. Irinogenetics: what is the right star? J Clin Oncol. 2006 May 20; 24(15):2221-4.
    View in: PubMed
    Score: 0.249
  6. From bedside to bench to bedside to clinical practice: an odyssey with irinotecan. Clin Cancer Res. 2006 Mar 15; 12(6):1658-60.
    View in: PubMed
    Score: 0.247
  7. "Irinogenetics" and UGT1A: from genotypes to haplotypes. Clin Pharmacol Ther. 2004 Jun; 75(6):495-500.
    View in: PubMed
    Score: 0.218
  8. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol. 2003 Dec; 14(12):1783-90.
    View in: PubMed
    Score: 0.211
  9. Pharmacogenomics: road to anticancer therapeutics nirvana? Oncogene. 2003 Sep 29; 22(42):6621-8.
    View in: PubMed
    Score: 0.208
  10. Irinotecan treatment in cancer patients with UGT1A1 polymorphisms. Oncology (Williston Park). 2003 May; 17(5 Suppl 5):52-5.
    View in: PubMed
    Score: 0.202
  11. Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"? J Clin Oncol. 2002 Jan 01; 20(1):7-8.
    View in: PubMed
    Score: 0.185
  12. Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. Drug Metab Dispos. 2001 Apr; 29(4 Pt 2):596-600.
    View in: PubMed
    Score: 0.175
  13. Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). Clin Cancer Res. 2021 01 01; 27(1):267-275.
    View in: PubMed
    Score: 0.169
  14. Insights into the pharmacokinetics and pharmacodynamics of irinotecan. Clin Cancer Res. 2000 Sep; 6(9):3393-4.
    View in: PubMed
    Score: 0.168
  15. Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies. Clin Cancer Res. 1999 Jun; 5(6):1325-30.
    View in: PubMed
    Score: 0.154
  16. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 1998 Feb 15; 101(4):847-54.
    View in: PubMed
    Score: 0.141
  17. Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). Cancer Chemother Pharmacol. 1998; 42(1):84-7.
    View in: PubMed
    Score: 0.140
  18. Clinical pharmacology of camptothecins. Cancer Chemother Pharmacol. 1998; 42 Suppl:S31-43.
    View in: PubMed
    Score: 0.140
  19. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol. 1997 Apr; 15(4):1502-10.
    View in: PubMed
    Score: 0.133
  20. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol. 1997; 39(5):440-4.
    View in: PubMed
    Score: 0.131
  21. Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity. J Clin Oncol. 1996 Jul; 14(7):2012-9.
    View in: PubMed
    Score: 0.126
  22. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A. Cancer Res. 1996 Mar 15; 56(6):1309-14.
    View in: PubMed
    Score: 0.124
  23. Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study. Pharmacogenomics J. 2016 Feb; 16(1):54-9.
    View in: PubMed
    Score: 0.116
  24. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 1994 Jul 15; 54(14):3723-5.
    View in: PubMed
    Score: 0.110
  25. The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients. Cancer Chemother Pharmacol. 2011 Dec; 68(6):1629-32.
    View in: PubMed
    Score: 0.090
  26. The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation. Eur J Cancer. 2010 Jul; 46(11):2097-103.
    View in: PubMed
    Score: 0.083
  27. Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan. Pharmacogenomics. 2009 Jul; 10(7):1139-46.
    View in: PubMed
    Score: 0.078
  28. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol. 2009 Jun 01; 27(16):2604-14.
    View in: PubMed
    Score: 0.076
  29. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin. 2009 Jan-Feb; 59(1):42-55.
    View in: PubMed
    Score: 0.075
  30. Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551. Cancer Chemother Pharmacol. 2009 Apr; 63(5):793-8.
    View in: PubMed
    Score: 0.073
  31. Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet? Pharmacotherapy. 2008 Jun; 28(6):755-68.
    View in: PubMed
    Score: 0.072
  32. The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol. 2007 Jan; 47(1):78-86.
    View in: PubMed
    Score: 0.065
  33. Effects of green tea compounds on irinotecan metabolism. Drug Metab Dispos. 2007 Feb; 35(2):228-33.
    View in: PubMed
    Score: 0.065
  34. TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy? Trends Pharmacol Sci. 2006 Aug; 27(8):432-7.
    View in: PubMed
    Score: 0.063
  35. Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes. Clin Cancer Res. 2005 Sep 15; 11(18):6699-704.
    View in: PubMed
    Score: 0.060
  36. Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer. Cancer Chemother Pharmacol. 2005 Oct; 56(4):421-6.
    View in: PubMed
    Score: 0.058
  37. Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. Pharmacogenet Genomics. 2005 May; 15(5):295-301.
    View in: PubMed
    Score: 0.058
  38. A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. Clin Pharmacol Ther. 2004 Nov; 76(5):490-502.
    View in: PubMed
    Score: 0.056
  39. Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2004 Apr 15; 22(8):1439-46.
    View in: PubMed
    Score: 0.054
  40. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004 Apr 15; 22(8):1382-8.
    View in: PubMed
    Score: 0.054
  41. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics. 2002 Dec; 12(9):725-33.
    View in: PubMed
    Score: 0.049
  42. Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide. Clin Pharmacol Ther. 2002 Dec; 72(6):638-47.
    View in: PubMed
    Score: 0.049
  43. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice. Cancer Chemother Pharmacol. 2002 Apr; 49(4):336-41.
    View in: PubMed
    Score: 0.046
  44. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002; 2(1):43-7.
    View in: PubMed
    Score: 0.046
  45. Pharmacogenetics: a tool for individualizing antineoplastic therapy. Clin Pharmacokinet. 2000 Nov; 39(5):315-25.
    View in: PubMed
    Score: 0.043
  46. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther. 1999 May; 65(5):576-82.
    View in: PubMed
    Score: 0.038
  47. A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer. Ann Oncol. 1998 Oct; 9(10):1085-90.
    View in: PubMed
    Score: 0.037
  48. Promising new agents in oncologic treatment. Curr Opin Oncol. 1996 Nov; 8(6):525-34.
    View in: PubMed
    Score: 0.032
  49. The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds. Cancer Chemother Pharmacol. 2009 Apr; 63(5):881-7.
    View in: PubMed
    Score: 0.018
  50. UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers. Pharmacogenet Genomics. 2007 Aug; 17(8):619-27.
    View in: PubMed
    Score: 0.017
  51. Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes. Pharmacogenet Genomics. 2006 Feb; 16(2):79-86.
    View in: PubMed
    Score: 0.015
  52. Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel. J Clin Oncol. 1996 Jun; 14(6):1964-5.
    View in: PubMed
    Score: 0.008
  53. Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study. J Clin Oncol. 1995 Sep; 13(9):2230-7.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.